SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is trending as its community aggressively rallies to push the token past key market capitalization milestones through active social engagement and coordinated buying challenges. Investors are drawn to the project's 'dark side' aesthetic and anti-rug pull narrative, which focuses on organic growth rather than traditional charts or celebrity-driven hype.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESH Acquisition Corp is experiencing significant investor interest driven by its status as a low-float SPAC, leading to high volatility and multiple trading halts. The community is actively debating the potential for a massive price squeeze, with many users drawing parallels to other recent high-momentum SPAC runs while debating the sustainability of the current price action.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is trending as investors gear up for the anticipated April 13th topline data readout from the Phase 2/3 OptimUM-02 trial evaluating Darovasertib and Crizotinib in metastatic Uveal Melanoma. The community is heavily focused on whether the Progression-Free Survival and Overall Response Rate results will meet the high bar required for an Accelerated Approval filing, with sentiment bolstered by strong institutional interest and the company's robust balance sheet.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is gaining significant momentum as the primary liquidity hub on the Base ecosystem, driven by anticipation surrounding its upcoming event and the broader potential of the Base network. Community discussion is heavily focused on the protocol's strong revenue-generating fundamentals, recent buyback activity, and bullish outlook regarding upcoming cross-chain developments.

Texas Pacific Land Corp. operates as a landowner in the State of Texas. Its surface and royalty ownership allow revenue generation through the entire value chain of oil and gas development, including through fixed fee payments for use of the firm's land, revenue for sales of materials used in the construction of infrastructure, providing sourced water and treated produced water, revenue from its oil and gas royalty interests, and revenues related to saltwater disposal on land. The firm also generates revenue from pipeline, power line and utility easements, commercial leases, material sales and seismic and temporary permits related to a variety of land uses including midstream infrastructure projects and hydrocarbon processing facilities. It operates through the Land and Resource Management and Water Services and Operations segment. The Land and Resource Management segment focuses on managing oil and gas royalty interest and surface. The Water Services and Operations segment refers to the full-service water offerings to operators in the Permian Basin through Texas Pacific Water Resources LLC, a single member Texas limited liability company owned by the company. The company was founded in 1871 and is headquartered in Dallas, TX.

Texas Pacific Land Corporation

Texas Pacific Land is seeing significant volatility as market participants process its recent inclusion in the S&P 500 alongside a broader strategic shift toward AI-related infrastructure projects, such as data centers. While the community remains divided between those viewing the rapid price appreciation as an overheated bubble and those betting on the company's long-term value as a unique land and resource owner, the stock continues to attract intense attention due to its low float and shifting control dynamics.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the Consumer and Business segments. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

Verizon is seeing a massive surge in investor interest following strong earnings that highlighted record subscriber growth and a new multi-billion dollar share repurchase program. The community is sharply divided, with bulls pointing to the company's dividend reliability and successful strategic turnaround under new leadership, while bears remain skeptical, citing heavy debt loads and concerns over subscriber reporting metrics.

Diodes Inc. engages in the manufacturing and supply of application-specific standard products within the broad discrete, logic, analog, and mixed-signal semiconductor markets. The firm offers diodes, rectifiers, transistors, MOSFETs, protection devices, functional specific arrays, single gate, dual gate and standard logic, amplifiers and comparators, Hall-effect, and temperature sensors. It operates through the following geographical segments: Asia, the Americas, and Europe. The company was founded on June 15, 1959 and is headquartered in Plano, TX.

Diodes, Inc.

Diodes Incorporated (DIOD) is drawing attention as market participants weigh its solid earnings performance against broader semiconductor sector cyclicality and inventory normalization trends. While some investors are monitoring the stock for potential breakout opportunities driven by its role in automotive and AI applications, others are cautious due to mixed analyst ratings and the stock's consolidation near recent highs.

Hpohs888inu

The community is actively debating the growing integration between Tether and the video platform Rumble, specifically regarding potential cloud computing partnerships and advertising synergies. While some participants discuss the strategic implications of these crypto-linked business deals, others are calling for increased moderation to address the high volume of automated spam posts surrounding the topic.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound is trending as investors debate whether the protocol's nearing max supply and recent governance updates signal an undervalued turnaround or a long-term decline compared to competitors like AAVE. The community is sharply divided, with some actively accumulating at current levels in anticipation of a supply-side squeeze, while others express frustration over stagnant price action and perceived mismanagement.

Digimarc Corp. provides digital watermarking technology services. It develops solutions, licenses intellectual property, and provides development services. The company also connects print, audio, and packaging to brand-defined online content, protects, identifies, and tracks digital files, and confirms content and objects are genuine, unaltered, and from an authorized source. Its products include Digimarc Validate, Digimarc Engage, Digimarc Recycle and Digimarc Retail Experience. The company was founded on January 3, 1995 and is headquartered in Beaverton, OR.

Digimarc Corporation

Digimarc is drawing heavy investor attention as the community anticipates a CUSIP change and closely watches short interest levels, fueling intense debate over management's ability to capitalize on the company's verification and trust-layer technology. Traders are actively monitoring potential contract catalysts while debating the company's long-term potential versus concerns regarding leadership's communication and execution strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?

Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

<ul class="summary-bullets"><li>The Gilead-Tubulis deal is aimed at expanding Gilead’s ADC capabilities by adding Tubulis’s assets that include its lead asset TUB-040.</li><li>According to Leerink analyst Andrew Berens, this acquisition serves as further validation of the antibody-drug conjugate space including Sutro Biopharma.&nbsp;</li><li>Leerink believes Sutro represents a similar set-up as Tubulis, although earlier in clinical development and technological validation.</li></ul><p>Gilead Sciences, Inc. (GILD) said on Tuesday that it has entered into a definitive agreement to acquire a private German clinical-stage biotechnology company, Tubulis GmbH, a move that investment bank Leerink believes should be a tailwind for other antibody-drug conjugate (ADC) platform companies like Sutro Biopharma.</p><p>STRO shares rose 7% at the time of writing while GILD fell 1%.</p><h2 class="st-heading-2">Gilead-Tubulis Agreement Terms</h2><p>Under the terms of the deal, Gilead will acquire all of the outstanding equity of Tubulis for $3.15 billion in upfront cash consideration, and up to $1.85 billion in contingent milestone payments.</p><p>The move is aimed at expanding Gilead’s Antibody-drug conjugates capabilities by adding Tubulis’s assets, including its lead asset TUB-040 which is in development to treat certain ovarian cancer and non-small cell lung cancer patients.</p><p>The transaction is expected to close in the second quarter of 2026, Gilead said.</p><p>ADCs are targeted biopharmaceutical cancer treatments that deliver potent cancer drugs directly to cancer cells while minimizing healthy tissue damage.</p><h2 class="st-heading-2">Leerink Weighs In</h2><p>According to Leerink analyst Andrew Berens, this acquisition serves as further validation of the ADC space and should be a tailwind for other ADC platform companies ,including Sutro Biopharma (STRO), as well as Immunome (IMNM) and Zymeworks (ZYME). This deal underscores the strategic value of an ADC discovery platform anchored to a lead asset to large pharma, Berens said.</p><p>However, while there are a number of similarities between Tubulis' platform and portfolio and that of Sutro, it is possible the acquisition price may have been supported by potential expansion of the Tubulis chemistry and technology beyond oncology and into inflammation and virology, Leerink said, as per TheFly. Leerink believes Sutro represents a similar set-up, although earlier in clinical development and technological validation.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around GILD stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume &nbsp;stayed at ‘high’ levels.</p><p>Meanwhile, sentiment around STRO stock remained ‘bullish,’ coupled with ‘low’ message volume.</p><p>While <a href="https://stocktwits.com/symbol/GILD">GILD shares</a> have risen 31% this year, <a href="https://stocktwits.com/symbol/STRO">STRO stock</a> has nearly quadrupled.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-launches-higher-dose-of-wegovy-injection-across-us/cZJJyAuRIpU">Novo Nordisk Launches Higher Dose Of Wegovy Injection Across US — Retail Thinks Stock Is ‘Terribly Undervalued’</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Gilead Sciences company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Gilead-Tubulis $5B Deal Gives STRO Stock A Boost — Here’s Why

Gilead said earlier on Tuesday that it will acquire Tubulis for up to $5 billion. 

Equity

Gilead said earlier on Tuesday that it will acquire Tubulis for up to $5 billion. 



Sutro Biopharma (NASDAQ:STRO) Coverage Initiated by Analysts at Leerink Partners

Leerink Partners initiated coverage on shares of Sutro Biopharma in a report on Tuesday. They set an "outperform" rating and a $38.00 price objective for the company...

Wave Life Sciences (WVE) Surges 9.5%: Is This an Indication of Further Gains?

Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Sutro Biopharma (NASDAQ:STRO) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen raised Sutro Biopharma from a "sell" rating to a "hold" rating in a report on Saturday...

HC Wainwright Lowers Earnings Estimates for Sutro Biopharma

Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Analysts at HC Wainwright decreased their Q1 2026 earnings per share estimates for Sutro Biopharma in a report issued on Tuesday, March 24th. HC...

Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Sutro Biopharma (NASDAQ:STRO) Stock Price

Deutsche Bank Aktiengesellschaft upped their target price on shares of Sutro Biopharma from $51.00 to $55.00 and gave the stock a "buy" rating in a research report on Wednesday...

HC Wainwright Predicts Sutro Biopharma FY2030 Earnings

Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Investment analysts at HC Wainwright issued their FY2030 EPS estimates for Sutro Biopharma in a report issued on Tuesday, March 24th. HC Wainwright...

Sutro Biopharma (NASDAQ:STRO) Raised to "Overweight" at Wells Fargo & Company

Wells Fargo & Company upgraded Sutro Biopharma from an "equal weight" rating to an "overweight" rating and increased their price objective for the stock from $8.00 to $27.00 in a research note on Tuesday...

Sutro Biopharma (NASDAQ:STRO) Raised to Buy at HC Wainwright

HC Wainwright raised Sutro Biopharma from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $10.00 to $28.00 in a research report on Tuesday...

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$2.63	--	--	N/A
Q4 '25	-$8.16	-$5.29	35.19%	BEAT
Q3 '25	-$0.39	-$6.70	-1598.54%	MISSED
Q2 '25	-$0.38	-$0.14	63.39%	BEAT
Q1 '25	-$0.64	-$0.91	-41.62%	MISSED

STRO
Sutro Biopharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest STRO News

STROSutro Biopharma Inc